¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"acute phase reactive protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • phase contrast
    À§»ó´ëÁ¶
  • phase curve
    À§»ó°î¼±
  • phase delay
    À§»óÁö¿¬
  • relaxation phase
    À̿ϱâ, À̿ϻó
  • resolution phase
    ÇØ¼Ò±â
  • resting phase
    1. È޽ıâ 2. »çÀ̱â
  • rigid erection phase
    °æÃà¹ß±â±â
  • solid phase
    °íü»ó
  • solid phase radioimmunoassay
    °íü»ó¹æ»ç¸é¿ªÃøÁ¤(¹ý)
  • spin phase
    ½ºÇÉÀ§»ó
  • spin phase effect
    ½ºÇÉÀ§»óÈ¿°ú
  • stance phase
    µðµõ±â, ÀÔ°¢±â
  • stationary phase
    Á¦ÀÚ¸®¼ºÀå±â
  • sucking phase
    »¡±â´Ü°è
  • swing phase
    Èçµê±â, À¯°¢±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • zygotene phase
    Á¢ÇÕ±â
  • solid phase radioimmunoassay
    °íÇü»ó¹æ»ç¸é¿ªÃøÁ¤(¹ý)
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • premiotic phase
    Çٺп­Àü±â(ú·ÝÂæñîñÑ¢).
  • preovulatory phase
    ¹è¶õÀü±â(ÛÉÕ°îñÑ¢).
  • progestational phase
    Ȳü±â(üÜô÷Ñ¢).
  • proleptotene phase
    Dz¼¶À¯±â
  • proliferation phase
    Áõ½Ä±â(ñòãÖÑ¢).
  • proliferative phase
    Áõ½Ä±â
  • regeneration phase
    Àç»ý±â(î¢ßæÑ¢) ¡ìÀڱ󻸷ÀÇ¡í.
  • relaxation phase
    À̿ϻó(ì¬èÐßÓ).
  • Burkitts acute lymphoblastic leukemia
    ¹öŰƮ ±Þ¼º ¸²ÇÁ¾Æ±¸¼º ¹éÇ÷º´
  • TWAR strain => Taiwan acute respiratory strain
    ŸÀ̿ϱ޼º È£Èí±â±ÕÁÖ, TWAR ±ÕÁÖ
  • Taiwan acute respiratory strain
    ŸÀ̿ϱ޼º È£Èí±â±ÕÁÖ
  • acute mixed-lineage leukmia
    ±Þ¼º È¥ÇÕÁ÷°è¼º ¹éÇ÷º´
  • acute abdomen =abdominal emergencies
    ¼Ò¾Æ°ú ±Þ¼ºº¹Áõ(¡­ÜÙñø).
  • acute abdomen =abdominal emergencies
    ±Þ¼ºº¹Áõ(¡­º¹Áõ).
  • acute alcoholism
    ±Þ¼º ¾ËÄÚ¿ÃÁßµ¶(Áõ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • specific protein
    ƯÀ̴ܹéÁú(÷åì¶Ó±ÛÜòõ).
  • sphingolipid activator protein I deficiency
  • spindle protein
    ¹æÃßü´Ü¹éÁú(¡­ô÷Ó±ÛÜòõ).
  • stable plasma protein solution =SPPS
    ¾ÈÁ¤Ç÷Àå(´Ü¹é)¿ë¾×(¡­úìíìÓ±ÛÜéÁ äû).
  • structural protein
    ±¸Á¶ ´Ü¹éÁú
  • structural protein
    ±¸Á¶ ´Ü¹é
  • tamm-horsfall protein
    Ž-È£½ºÆú´Ü¹é
  • thyroxin binding protein
    Ƽ·Ï½Å°áÇմܹéÁú(¡­Ì¿ùêÓ±ÛÜòõ).
  • tidal plasma protein
    ¼øÈ¯Ç÷Àå´Ü¹é·®(âàü»úìíìÓ±ÛÜåÖ).
  • tissue protein
    Á¶Á÷´Ü¹éÁú(¡­Ó±ÛÜòõ).
  • total protein
    ÃѴܹ鷮(õÅÓ±ÛÜåÖ).
  • total serum protein
    ÃÑÇ÷û´Ü¹é(·®).
  • vehicle protein
    ´Ü¹éÁú(Ó±ÛÜòõ)¿î¹ÝÀÚ.
  • viral protein
    ¹ÙÀÌ·¯½º´Ü¹é(¡­Ó±ÛÜ).
  • viral protein (VP)
    ¹ÙÀÌ·¯½º ´Ü¹é
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
  • protein overloading
    ´Ü¹éÁú°úºÎÇÏ(Ó±ÛÜòõΦݶùÃ)
  • protein processing
    ´Ü¹éÁú °¡°ø(Ó±ÛÜòõÊ¥Íï)
  • protein release factor
    ´Ü¹éÁú ¹æÃâÀÎÀÚ(Ó±ÛÜòõÛ¯õóì×í­)
  • protein score
    ´Ü¹éÁú°¡(Ó±ÛÜòõʤ)
  • protein sequencer
    ´Ü¹éÁú¼­¿­±â(Ó±ÛÜòõßíÖªÐï)
  • protein sequencing
    ´Ü¹éÁú ¼­¿­ °áÁ¤(Ó±ÛÜòõßí֪̽ïÒ)
  • protein-sparing action
    ´Ü¹éÁú Àý¾à ÀÛ¿ë(Ó±ÛÜòõï½å³íÂéÄ)
  • protein structure
    ´Ü¹éÁú ±¸Á¶(Ó±ÛÜòõϰðã)
  • protein synthesis
    ´Ü¹éÁú ÇÕ¼º(Ó±ÛÜòõùêà÷)
  • protein synthesis factor
    ´Ü¹éÁú ÇÕ¼ºÀÎÀÚ(Ó±ÛÜòõùêà÷ì×í­)
  • protein-synthesizing system
    ´Ü¹éÁú ÇÕ¼º(Ó±ÛÜòõùêà÷) ½Ã½ºÅÛ
  • protein turnover
    ´Ü¹éÁú Àüȯ(Ó±ÛÜòõï®üµ)
  • protein value
    ´Ü¹éÁú(Ó±ÛÜòõ)°ª
  • read-through protein
    ÆÇµ¶ ´Ü¹éÁú(÷÷ÔÁÓ±ÛÜòõ)
  • Rec A protein
    Rec A ´Ü¹éÁú(Ó±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
REPS reactive extensor postural synergy
RH radiant heat; radiation hybrid; radiological health; reactive hyperemia; recurrent herpes; regulator...
RHBF reactive hyperemia blood flow
RND radical neck dissection; radionuclide dacryography; reactive neurotic depression
ROI reactive oxygen intermediate; region of interest; right occipitolateral [fetal position]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 14
RP HPLC Reversed phase high performance liquid chromatography
RP Reverse phase
RP-HPLC Reverse-phase-HPLC
RPC Reversed Phase Chromatography
RP-HPLC Reversed phase high performance liquid chromatographic
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute orchitis
    ±Þ¼º °íȯ¿°
  • acute pain
    ±Þ¼º ÅëÁõ, ±Þ¼º µ¿Åë
    1. À¯¹ß ÀÎÀÚ³ª ¿øÀÎ ÀÎÀÚµéÀÌ Á¤»óÀ¸·Î µÇ´Âµ¥ ÇÊ¿äÇÑ ½Ã°£À̳ª Á¤»óÀûÀÎ Ä¡À¯ ±â°£ ³»¿¡ Á¦ÇÑµÇ¾î ³ªÅ¸³ª´Â ºÒÄèÇÑ °¨°¢. ÀüÅëÀûÀÎ Á¤ÀÇ¿¡ ÀÇÇϸé 6°³¿ù ¹Ì¸¸ÀÇ ±â°£ÀÌ´Ù. 2. ª°í ºñ±³Àû ½ÉÇÑ ÇüÅÂÀÇ µ¿Åë.
  • acute papular onchodermatitis
    ±Þ¼º ±¸Áø¼º ȸ¼±»ç»óÃæ ÇǺο°
  • acute pathologic pain
    ±Þ¼º º´¸®Àû µ¿Åë
  • acute periapical infection
    ±Þ¼º Ä¡±Ù´Ü °¨¿°
  • acute perichondritis
    ±Þ¼º ¿¬°ñ¸·¿°
  • acute periodontal abscess
    ±Þ¼º Ä¡ÁÖ ³ó¾ç
  • acute peritonitis
    ±Þ¼º º¹¸·¿°
    ¼¼±ÕÀÇ Ä§¹üÀ̳ª È­ÇÐÀû Àڱؿ¡ ÀÇÇØ¼­ »ý±æ ¼öµµ ÀÖÀ¸³ª °¡Àå ÈçÇÑ ¿øÀÎÀº ±Þ¼º Ãæ¼ö¿°À̳ª ¼ÒÈ­¼º ±Ë¾ç¿¡ ÀÇÇÑ Ãµ°ø µî ³»°­ÀÌ ÀÖ´Â Àå±âÀÇ Ãµ°ø¿¡ ÀÇÇÑ ¼¼±Õ¼º º¹¸·¿°ÀÌ´Ù. °ÅÀÇ Ç×»ó ³»Àå º®À» ÅëÇÑ ¼¼±ÕÀÇ ÆÄ±Þ ¶Ç´Â ³»ºÎ Àå°üÀÇ ÆÄ¿­¿¡ ÀÇÇØ ÀÌÂ÷ÀûÀ¸·Î »ý±ä´Ù.
  • acute pharyngitis
    ±Þ¼º Àεο°
    ±¸Çù, ÀεÎÀÇ Á¡¸· ¹× ¸²ÇÁ Á¶Á÷ÀÇ ±Þ¼º ¿°ÁõÀÌ´Ù. ¹ÙÀÌ·¯½º, ¼¼±Õ °¨¿°, ¶Ç ¹°¸®È­ÇÐÀû Àڱؿ¡ ÀÇÇØ¼­ »ý±ä´Ù. Áõ»óÀº °æµµ ¶Ç´Â ÁߵÀÇ ¹ß¿­, ÀεÎÀÇ ºÒÄè°¨ ³»Áö ÀεÎÅë µîÀÌ´Ù. ÀεΠÁ¡¸·Àº ¹ßÀû Á¾Ã¢ÇÏ°í ¾ÇÇÏ ¸²ÇÁÀý Á¾Ã¢À» ¼ö¹ÝÇÑ´Ù. ÇÕº´ÁõÀÌ ¾øÀ¸¸é °æ°ú´Â ¾çÈ£ÇÏ°í ¼öÀÏ¿¡¼­ 1ÁÖÀÏ Á¤µµ·Î Ä¡À¯ÇÑ´Ù. Ä¡·á´Â ¾ÈÁ¤, ÇÔ¼ö³ª ÈíÀÔ¿ä¹ý, ¼Ò¿°Á¦, Ç×»ý ¹°ÁúÀÇ Åõ¿© µîÀÌ´Ù.
  • acute pneumonia
    ±Þ¼º Æó·Å
    ¹ÙÀÌ·¯½º, ¼¼±Õ µî¿¡ ÀÇÇØ¼­ »ý±â´Â Æó ½ÇÁúÀÇ ±Þ¼º ¿°ÁõÀÌ°í º´º¯ÀÇ Áß½ÉÀº ÆóÆ÷ »óÇÇ, ¼¼Æ÷ °­¿¡ ÀÖÀ¸¸ç, ÆóÆ÷³»¿¡ ´Ù·®ÀÇ Ä§Ãâ¹°ÀÌ Ãæ¸¸ÇØ X-¼± Çʸ§ »ó¿¡¼­´Â ±â°üÁö °­À» Á¦¿ÜÇÏ°í ±ÕµîÇÑ ±×¸²ÀÚ·Î µÚµ¤ÀδÙ. Àü¿¡´Â °¨¿° Áúȯ Áß »óÀ§¸¦ Â÷ÁöÇϰí ÀÖ¾ú´Âµ¥ Ç×»ý ¹°ÁúÀÇ µîÀåÀ¸·Î °Ý°¨Çß´Ù. ÃÖ±Ù¿¡´Â ¿ø³»°¨¿°¿¡ µû¸¥ ³­Ä¡ÀÇ ±×¶÷ À½¼º±Õ °¨¿°ÀÌ Áõ°¡ Ãß¼¼¿¡ ÀÖ´Ù.
  • acute poliomyelitis
    ±Þ¼º ȸ¹éô¼ö¿°, ±Þ¼º ¼Ò¾Æ¸¶ºñ
    »ê¹ßÀûÀ¸·Î ¹ß»ýÇÏ´Â ±Þ¼º ¹ÙÀÌ·¯½º ÁúȯÀ¸·Î ¹ß¿­, ÀεΠ¹ßÀû, µÎÅë, ±¸Åä µîÀ» Ư¡À¸·Î ÇÏ°í ¸ñ´ú¹Ì¿Í µî ÂÊ ºÎºÐÀÇ °­Á÷À» µ¿¹ÝÇÑ´Ù.
  • acute poststreptococcal glomerulonephritis
    ±Þ¼º ¿¬¼â»ó ±¸±Õ¼º »ç±¸Ã¼ ½Å¿°
    A±º ¿¬¼â»ó ±¸±Õ °¨¿°ÀÌ ¿øÀÎÀÌ µÇ¾î ¹ß»ýÇÏ´Â ±Þ¼º ½Å¿°ÀÌ´Ù. ¿¬¼â»ó ±¸±Õ¿¡ ÀÇÇÑ Æíµµ¿° µîÀÌ Ä¡À¯µÇ¾î¼­ 1-2ÁÖ ÈÄ¿¡ µ¹¿¬ ºÎÁ¾, ÇÌ´¢, °íÇ÷¾Ð µîÀ» µ¿¹ÝÇØ¼­ ¹ßº´ÇÑ´Ù. ¼Ò¾Æ¿¡ ¸¹ÀÌ ¹ßº´Çϳª ¼ºÀο¡°Ôµµ µå¹°Áö´Â ¾ÊÀ¸¸ç, ¾à 90%´Â 1-2°³¿ù ÈÄ¿¡ ¿ÏÀüÈ÷ Ä¡À¯µÈ´Ù. Ç÷û ASLO °ªÀÇ »ó½Â°ú Ç÷û º¸Ã¼°¡ÀÇ °¨¼Ò°¡ Áø´Ü¿¡ µµ¿òÀÌ µÈ´Ù. ÀÌ Áõ»óÀº ¿¬¼â»ó ±¸±ÕÀÇ Ç׿ø°ú ±× Ç×ü¿¡ ÀÇÇÑ ¸é¿ª º¹ÇÕü ½Å¿°ÀÌ´Ù. ƯÈ÷ ¼Ò¾Æ¿¡¼­´Â ±Þ¼º±â¿¡ °íÇ÷¾Ð¿¡ ÀÇÇÑ ½ÉºÎÀü, °æ·ÃÀ» ÀÏÀ¸Å°±â ½±±â ¶§¹®¿¡ ÁÖÀǸ¦ ¿äÇÑ´Ù.
  • acute pseudomembranous candidosis
    ±Þ¼º À§¸·¼º ĵµð´ÙÁõ
  • acute psychologic distress
    ±Þ¼ºÀÇ Á¤½ÅÀû °íÅë
  • acute pulpitis
    ±Þ¼º Ä¡¼ö¿°
    Ä¡¼öÀÇ ±Þ¼º ¿°ÁõÀÌ´Ù. Ä¡¾Æ¿ì½ÄÁõÀ¸·Î ÀÕµû¶ó ¹ß»ýÇÏ´Â °Í°ú ¿Ü»óÀÌ ¿øÀÎÀÎ °ÍÀ¸·Î ±¸ºÐÇÑ´Ù. ¸ðµÎ ½ÉÇÑ ÅëÁõÀÌ ÁÖµÈ Áõ»óÀÌ´Ù. ÈÄÀÚ¿¡ À־´Â ÁøÅëÁ¦ Åõ¿©·Î Áõ»óÀÌ °¡¶ó¾É´Â °ÍÀÌ ¸¹Àºµ¥, ÀüÀÚÀÇ °æ¿ì ÁøÅëÁ¦·Î È¿°ú°¡ ¾ø°í, ¹ßÄ¡ÇÏÁö ¾ÊÀ¸¸é ¾È µÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 14
acute miliary tuberculosis A rapidly fatal disease due to the general dissemination of tubercle bacilli in the blood, resulting in the formation of miliary tubercles in various organs and tissues, and producing symptoms of profound toxaemia.
Synonym: acute miliary tuberculosis, disseminated tuberculosis.
(05 Mar 2000)
acute monocytic leukaemia <haematology> The most common translocation in this disorder of poorly differentiated monocytic cells involves chromosome region 11q in a large percentage of cases.
The translocation involves a cellular oncogene, c-ets which is mapped to the 11q23-24 region. The most common translocations reported are t(6;11), t(9;11), t(11;17) and t(11;19), of which t(9;11) (p21-22;q23) is by far the most frequently detected and implicated in acute myeloid leukaemia. The cells express CD14 surface antigen, which is diagnostic of monocytic cells.
Acronym: AML
Classification: FAB M5
(07 Apr 1998)
acute mountain sickness <chest medicine> A condition that results from prolonged exposure to high altitude.
Symptoms include a continuous dry cough, shortness of breath, poor exercise tolerance, dizziness, headache, sleep difficulty, anorexia, confusion, fatigue and a rapid pulse.
Treatment includes the immediate movement to a lower altitude. Prophylaxis has been accomplished successfully with the use of acetazolamide (Diamox).
(27 Sep 1997)
acute myeloblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myelogenous leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myeloid leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute necrotizing encephalitis An acute form of encephalitis, characterised by destruction of brain parenchyme.
(05 Mar 2000)
acute necrotizing haemorrhagic encephalomyelitis A fulminating demyelinating disorder of the central nervous system that affects mainly children and young adults. Almost always preceded by a respiratory infection, characterised by the abrupt onset of fever, headache, confusion, and nuchal rigidity, soon followed by focal seizures, hemiplegia, or quadriplegia, brainstem findings, and coma; the CSF shows evidence of an inflammatory process; due to the massive destruction of the white matter of one or both hemispheres, often accompanied by similar destruction of the white matter of the brainstem and cerebellar peduncles; of unknown aetiology.
Synonym: acute haemorrhagic leukoencephalitis, acute necrotizing haemorrhagic leukoencephalitis.
(05 Mar 2000)
acute necrotizing haemorrhagic leukoencephalitis A fulminating demyelinating disorder of the central nervous system that affects mainly children and young adults. Almost always preceded by a respiratory infection, characterised by the abrupt onset of fever, headache, confusion, and nuchal rigidity, soon followed by focal seizures, hemiplegia, or quadriplegia, brainstem findings, and coma; the CSF shows evidence of an inflammatory process; due to the massive destruction of the white matter of one or both hemispheres, often accompanied by similar destruction of the white matter of the brainstem and cerebellar peduncles; of unknown aetiology.
Synonym: acute haemorrhagic leukoencephalitis, acute necrotizing haemorrhagic leukoencephalitis.
(05 Mar 2000)
acute necrotizing myelitis A spinal cord disorder, probably a demyelinating disease, which affects persons of all ages and either sex. Presents with abrupt or more gradual onset with sensory abnormalities and upper motor neuron weakness; soon a reflexic flaccid motor paralysis and sphincter paralysis supervenes, which is permanent. In some, but not all cases, bilateral or unilateral optic neuritis is associated. In the cerebrospinal fluid, the protein is increased, and mononuclear cells are present. After autopsy, the lesion has been identified as a necrotizing haemorrhagic leukomyelitis.
(05 Mar 2000)
acute necrotizing ulcerative gingivitis An acute or recurrent gingivitis of young and middle-aged adults characterised clinically by gingival erythema and pain, fetid odour, and necrosis and sloughing of interdental papillae and marginal gingiva which gives rise to a gray pseudomembrane; fever, regional lymphadenopathy, and other systemic manifestations also may be present. A fusiform bacillus and Treponema vincentii can be isolated from the gingival tissues in large numbers and are felt to play a significant but poorly defined role in the pathogenesis.
Synonym: fusospirochetal gingivitis, trench mouth, ulceromembranous gingivitis, Vincent's disease, Vincent's infection.
(05 Mar 2000)
acute nephritic syndrome <nephrology, syndrome> A disease of the kidneys that results in inflammation of the glomerulus (the portion of the kidney that filters the blood).
Conditions which may cause glomerulonephritis include post-streptococcal disease (strep throat), lupus, syphilis, bacterial endocarditis, membranoproliferative glomerulonephritis, sepsis, vasculitis, Goodpasture's syndrome, typhoid fever, Henoch-Schonlein purpura, hepatitis or a viral infection (for example mumps, measles, mononucleosis).
(15 Jan 1998)
acute nephritis <nephrology> A disease of the kidneys that results in inflammation of the glomerulus (the portion of the kidney that filters the blood).
Conditions which may cause glomerulonephritis include post-streptococcal disease (strep throat), lupus, syphilis, bacterial endocarditis, membranoproliferative glomerulonephritis, sepsis, vasculitis, Goodpasture's syndrome, typhoid fever, Henoch-Schonlein purpura, hepatitis or a viral infection (for example mumps, measles, mononucleosis).
(27 Sep 1997)
acute nephrosis Acute oliguric renal failure, especially that caused by certain poisons.
(05 Mar 2000)
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 14
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 14
ÅëÇÕ°Ë»ö ¿Ï·á